Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Robert, Caroline; Grob, Jean‐Jacques; Stroyakovskiy, Daniil; Karaszewska, Bogusława; Hauschild, Axel; Levchenko, E.; Chiarion‐Sileni, Vanna; Schachter, Jacob; Garbe, Claus; Bondarenko, Igor; Gogas, Helen; Mandalà, Mario; B.A.G. Haanen, John; Lebbé, Célèste; Maćkiewicz, Andrzej; Rutkowski, Piotr; Nathan, Paul; Ribas, Antoni; A. Davies, Michael; T. Flaherty, Keith; Burgess, Paul; Tan, Monique; Gasal, Eduard; Voi, Maurizio; Schadendorf, Dirk; V. Long, Georgina

doi:10.1056/nejmoa1904059

Public

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Published in New England Journal of Medicine • Jun 4, 2019

Authors:

Caroline Robert

Jean‐Jacques Grob

Daniil Stroyakovskiy

Abstract

BACKGROUND: V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristic...

Subject

Dabrafenib

Trametinib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!